Joaquín Herrera retweetledi
This conversation with @RickRubin is special. Here's a 2 minute preview that I’ve watched 15 times.
The episode will be out tomorrow:
English
Joaquín Herrera
1.2K posts
Joaquín Herrera
@mpc60_
| founder @TakenosApp | porteño y argentino 🇦🇷
Buenos Aires Katılım Ağustos 2022
2.3K Takip Edilen687 Takipçiler
qué lindo ver de cerca una maquinita como @nacho_gorriti_ dando vuelta este mercado y dejando patas para arriba.
vamos @roomix_ai!
Nacho Gorriti@nacho_gorriti_
Cerramos una ronda de inversión en @roomix_ai para setear el standard de búsqueda con IA en real estate, con el apoyo de inversores como @adamdangelo, @rauchg, Charlie Songhurst, @cocoscap, @PicanteStartups y más 🚀 Arrancando en 🇦🇷.
Español
@ferminrp @meetgranola resuelve casi la totalidad de las cosas paja del trabajo.
Español
Pocas herramientas me ahorraron tanto laburo los ultimos meses como el MCP de @meetgranola. Pedirle a cualquier ai que actualice documentos en base a lo que se hablo en una reunion, que te recuerde que accionables te llevaste o a quien hacerle seguimiento y que lo haga ... hermoso.
go.granola.ai/twitter
Español
English
Vocabulary is doing most of the damage here. When a board-certified urologist defends "peptides" by pointing to GLP-1 trial data or Lutathera outcomes, the defense is technically accurate and completely irrelevant to BPC-157, because those compounds share a chemistry class and nothing else. The SELECT trial showing 20% MACE reduction, the NETTER-1 and NETTER-2 data for Lu-177 dotatate, the ESSENCE trial hitting 62.9% MASH resolution: none of that evidence transfers to a compound that has never completed a human RCT, full stop.
The "research use only" framing used by mail-order BPC-157 vendors exists precisely because FDA's Category 2 classification under 503A compounding creates an enforcement gap wide enough to drive a distribution business through. That gap is the actual regulatory story, and it rarely comes up in these reaction videos.
What distinguishes semaglutide from BPC-157 is not the peptide chemistry. It is receptor binding kinetics characterized across controlled dose-response trials in humans, replicated across independent programs, with outcomes data in hard clinical endpoints. BPC-157 has none of that architecture. Calling both "peptides" and then debating whether "peptides cause cancer" or "peptides have human RCTs" is a category error dressed up as a scientific dispute.
The deeper problem is that defenders of legitimate GLP-1 research and defenders of wellness peptides are often using the same vocabulary to mean completely different things, which makes the whole conversation almost impossible to resolve. What does Dr. Tatem actually say when the question is narrowed specifically to BPC-157's human outcomes data rather than peptide pharmacology in general?
onhealthcare.tech/p/the-peptide-…
English
BPC-157 causing cancer? FDA shutting down peptide trials?
“No human RCTs have ever been done on peptides?”
In this video, Dr. Alex Tatem — board-certified urologist and fellowship-trained men’s health specialist — reacts to viral claims made on @ShawnRyanShow about BPC-157, TB-500, peptides, angiogenesis, cancer risk, and peptide safety.
We break down:
• Whether BPC-157 actually causes cancer
• The truth about angiogenesis and tumor growth
• FDA regulation of peptides and compounding
• Why the “no randomized controlled trials” claim is completely false
• Human clinical trial data on peptides
• The real history of BPC-157 clinical studies
• Huberman’s correction of viral peptide misinformation
• Why peptide fearmongering could push patients toward unsafe gray-market sourcing
This is not bro-science or influencer hype. This is a deep dive into the actual published literature, peptide pharmacology, FDA policy, and performance medicine.
Topics covered include:
BPC-157, TB-500, peptides, angiogenesis, cancer biology, GLP-1 drugs, Ozempic, tirzepatide, semaglutide, TRT, peptide therapy, biohacking, longevity, anti-aging medicine, compounding pharmacies, peptide legality, @hubermanlab , @ShawnRyan762 Show, FDA peptide regulation, growth hormone history, and performance medicine.
If you’ve ever wondered whether BPC-157 is dangerous, whether peptides are legal, or whether the internet is fearmongering about peptide therapy — this video is for you.
English
English
@DanteReminick @0xbaer Build it in Takenos. We already help some ngos
English
@0xbaer Build the Fund to Fund the Build so we can Build Funds
English
English
@typesfast @ConorNeu Yes, not reporting sensitivity vs specificity is a red flag right off the bat
English
Joaquín Herrera retweetledi
Had a Jane Street phone interview in 2016. "Price a 6-month forward on carrots."
There's no carrot futures market, so I build one from scratch: seasonal harvest cycles, USDA demand elasticity, cold storage decay rates.
One trader stops me. "Your storage cost function– you're modeling the carrot as dead inventory. Like grain in a silo." He asks me the metabolic respiration rate of a post-harvest carrot at 2°C. I estimate.
"Your forward is overpriced by exactly that shrinkage. The underlying is consuming its own sugars. It's alive." Good correction. I adjust the model. I think I've recovered.
Rejection email comes the next morning. Subject: "Ethical Review." My framework, they write, "relied on the severance of the root organism from its growth medium." The question about respiration was a test. The carrot was still alive and I'd built an entire derivatives structure on top of its death without questioning whether harvest was an acceptable act.
I pull up the recruiter's original email. It doesn't say Jane Street. It says Jain Street– a non-violent quantitative commodities fund.
The carrot was never supposed to be priced. It was supposed to be refused. I later learn the only candidate who passed that round was a former monk from Gujarat who sat in silence for eleven minutes and said, "I cannot put a price on life." He's now a partner.
Deedy@deedydas
Jane Street made ~$40B in 2025 with 3,500 employees, a ~2x from the year before. At ~65-70% profit margin, that's $8M profit / employee, the highest for a 1000+ ppl company. High-frequency trading continues to be the most efficient money making engine. I want to share an old story about my Jane Street interview in 2014. Jane Street was known for hiring a lot of math, physics and CS olympiad winners from top universities and putting them through many rounds - including, for trading roles, a gauntlet of mental math. It was my 6th interview and my final round and I recall being asked "What is the next day after today in DD/MM/YYYY where all the digits are unique?" They'd toy with you and say "You can use a pencil and paper, if you want" but you knew that was an instant no. Painstakingly and as quickly as I could, I came to an answer. "How confident are you that this is correct on a 0-1 probability scale?" the interviewer said. "0.95", I blurted out, not fully knowing how to answer that. "Are you sure?" After thinking harder for a few more seconds, I realized I could've flipped the digits around to get a closer date. I gave the interviewer my answer. It was correct. "0.95 huh?" he chuckled. That's when I knew I failed. Note: fwiw, other companies that come close in efficiency are - Tether ($90M+ profit/emp) - Hyperliquid ($80M+ profit/emp) and on revenue: - Valve ($50M/emp) - OnlyFans ($37M/emp) - Craigslist ($14M/emp) - Anthropic ($12M/emp, run rate) - OpenAI ($8M/emp, run rate) For comparison, Nvidia is very efficient at scale and is $4.4M/emp.
English
Esta semana lanzamos un producto distinto. USDar (0xdcc340132740ad57e9fc90c9bd08b00dbbc87986)
Una stablecoin del dolar que en vez de llevarse los dolares del coalteral, los deja en Argentina. 100% respaldada por activos locales.
Ya se puede operar desde la app de Ripio (cotiza más parecido al dólar MEP que al dólar cable). Si tienen preguntas o quieren conocer más, mándenlas que nos ayuda a armar mejores FAQs y comunicación.
Todavía no está tan madura en DeFi como las wFiat, pero desde Ripio pueden enviar y recibir por mainnet si quisieran.
Ripio@RipioApp
¡Llegó $USDar! La primera stablecoin con paridad 1:1 con el dólar MEP 🚀 El nuevo Dólar Argentino tiene el MEJOR tipo de cambio del mercado cripto 🔥 100% respaldada por activos locales. ¿Qué podés hacer? 🔒 Holdear 💸 Transferir 🔄 Swapear Entrá a la app y conocé más en usd.ar 📲
Español
@HadickM This is already larger than stablecoin-backed cards. The addressable market is correspondent banking flows
English
Stablecoins connecting local RTP networks has become one the fastest growing payment markets in the world. Probably only beat by the growth in Stablecoin backed card settlement.
English
@impuestito_org hay algo q no termino de entender de tu pag, segun revise lo q mas conviene es pagar con takenos? queda 14k el mes de pc gamepass? y xq en el tw decis 17k? para saber mas que nada, asi queda claro!
Español
🔴 Bajó Game Pass en Argentina 🇦🇷
Precios con impuestos incluidos:
✅ Game Pass Ultimate: $30.749 ➡️ $23.369
✅ PC Game Pass: $18.449 ➡️ $17.219
(*) Precios pagando con tarjeta en USD
(*) Para más formas de pago entrá a la web de impuestito, ya está actualizado
impuestito.org@impuestito_org
Baja Xbox Game Pass ??? 👁️👄👁️ Hoy Xbox comunicó que baja el precio de Xbox Game Pass Ultimate y PC Game Pass en USA 🇺🇸 Ultimate: $30 a $23 PC Game Pass: $16.5 a $14 Es muy probable que baje el precio en Argentina 🇦🇷 también, los mantengo actualizados 🧐 Abajo la noticia 👇
Español
"Sueldos"
Porque esto es lo que ganan y así invierten los jóvenes en Buenos Aires al día de la fecha; el dato llamativo: lo que gana una streamer por mes.
Español
@TermobaricaJGM @3Cebolla y de otros países limítrofes y no limítrofes
Español
Ya va en varios lugares que veo que nombran Takenos para invertir, alguno la usa? Recomendan?
Tendencias en Argentina@porqueTTarg
"Sueldos" Porque esto es lo que ganan y así invierten los jóvenes en Buenos Aires al día de la fecha; el dato llamativo: lo que gana una streamer por mes.
Español
Más allá de que me destruye enterarme de lo que gana un streamer, alguien usa Takenos? Ya van varios que veo que la usan, la recomiendan?
Tendencias en Argentina@porqueTTarg
"Sueldos" Porque esto es lo que ganan y así invierten los jóvenes en Buenos Aires al día de la fecha; el dato llamativo: lo que gana una streamer por mes.
Español
Un taxista de Oruro ahora puede comprar SPY
@TakenosApp
Takenos 🌮@TakenosApp
Hoy lanzamos una nueva función: Inversiones, impulsado por @OndoFinance. Es un paso más en algo que venimos construyendo desde el día uno: hacer que las finanzas dejen de ser complejas. Cobrar, enviar, pagar… y ahora invertir, desde el celular.
Español
Bringing global markets to the most obscure places of latam
@OndoFinance 🫱🏻🫲🏾 @TakenosApp
Ondo Finance@OndoFinance
Tokenized stocks are expanding their reach. Ondo tokenized SPYon, QQQon, and GLDon are now integrated into @TakenosApp, a leading consumer finance app in LATAM.
English
English
@OndoFinance @TakenosApp This is huge for LATAM access to US markets. Curious how the UX compares to traditional brokers there, tokenized rails should be way smoother for cross border
English
Tokenized stocks are expanding their reach.
Ondo tokenized SPYon, QQQon, and GLDon are now integrated into @TakenosApp, a leading consumer finance app in LATAM.
Takenos 🌮@TakenosApp
Hoy lanzamos una nueva función: Inversiones, impulsado por @OndoFinance. Es un paso más en algo que venimos construyendo desde el día uno: hacer que las finanzas dejen de ser complejas. Cobrar, enviar, pagar… y ahora invertir, desde el celular.
English
Joaquín Herrera retweetledi
Look guys, it's actually really straightforward, a bunch of people staked their ETH on the Ethereum blockchain to earn yield, except they didn't want their capital to be locked up, so they actually staked with a liquid staking protocol called Lido who provided them a liquid staking receipt token called stETH, except they decided to juice their yield further by depositing their stETH receipt tokens into a restaking protocol called Eigenlayer, except they didn't want to lock up their capital, so they actually restaked with a liquid restaking protocol called KelpDAO who provided them with a liquid restaking receipt token called rsETH, except they decided to juice their yield further by depositing their rsETH tokens into a lending protocol called Aave so that they could open a leveraged looping position that borrows ETH against the rsETH collateral and restakes the ETH into rsETH which is then deposited as collateral, except it turns out rsETH used a cross-chain bridge called LayerZero that was hacked by north koreans causing rsETH to become undercollateralized and now these looping positions are stuck and unprofitable, and everyone is pointing fingers at each other, and also DeFi is a very serious industry
English